#1 Clinical Trials Search in Europe

Effect of ramipril, acetylsalicylic acid, and atorvastatin calcium trihydrate plus nurse education on treatment adherence in patients with acute coronary syndrome

1 1 1 1

What is this study about?

This study focuses on individuals who have experienced Acute Coronary Syndrome, a term used to describe a sudden decrease in blood flow to the heart that can cause a heart attack. The research aims to evaluate how a combination of a single pill containing multiple medications and a nurse-led education program affects how well patients follow their prescribed medical treatment. The medication being tested is a polypill known as Trinomia, which contains ramipril, acetylsalicylic acid, and atorvastatin. This pill is compared to taking the individual medications, Acovil, Cardyl, and Adiro, separately.

Participants in the study will be assigned to different groups to receive either the combined pill or the individual medications, along with a program where nurses provide educational support. The study will follow these individuals for one year after they are discharged from the hospital to see if this combined approach helps them stay consistent with their daily medication routine. The course of the study involves regular follow-ups to monitor how well the treatment plan is being followed and to observe various health factors.

Who Can Join the Study?

  • You must be an adult, which means you are a person who has reached legal adulthood.
  • You must have been admitted to the hospital for acute coronary syndrome, a term used to describe a sudden blockage or problem with blood flow to the heart.
  • Your condition must have shown signs of ischemia, which means your heart muscle was not getting enough oxygen-rich blood.
  • Your condition must have been confirmed by specific changes seen on an electrocardiogram (a test that records the electrical activity of your heart), such as changes in the heart’s electrical waves.
  • Your condition must have been confirmed by an elevated level of troponin, which is a specific protein released into the blood when the heart muscle is damaged.
  • You must have been admitted to one of the study centers between September 2024 and September 2026.

Who Cannot Join the Study?

  • You cannot participate if you have a contraindication, which means a medical reason or allergy that makes it unsafe for you to take any of the medicines included in the polypill.
  • You cannot join if you are unwilling or unable to provide informed consent, which is the formal agreement to participate in the study after being fully explained all the details and risks.
  • You cannot participate if you are unable to complete the clinical follow-up, which refers to the scheduled medical check-ups and appointments required throughout the study.
  • You cannot be part of the study if you are living in a long-term care facility or a nursing home when you join the study or at any point during the one-year period of the research.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Bellvitge University Hospital L'hospitalet De Llobregat Spain

Other Sites

No sites found in this category

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Not yet recruiting
01.03.2026

Trial locations

Investigated drugs:

Trinomia is a combination pill that contains three different medicines: ramipril, which helps lower blood pressure; aspirin, which prevents blood clots from forming; and atorvastatin, which helps lower cholesterol levels. This pill is being tested to see if taking one combined medication improves how well patients follow their treatment.

Acovil is a medication containing ramipril, which is used to help manage blood pressure and protect the heart.

Cardyl contains atorvastatin, a medicine used to lower cholesterol levels in the blood.

Adiro contains aspirin, which is used to prevent blood clots that could lead to heart problems.

Investigated diseases:

Acute coronary syndrome – This condition occurs when the blood flow to the heart muscle is suddenly reduced or blocked. It is typically caused by a buildup of fatty substances and other materials in the arteries that supply the heart. This blockage can lead to a sudden decrease in oxygen reaching the heart tissue. The condition can manifest as a variety of related events, such as unstable angina or a heart attack. As the blockage persists, it can cause damage to the heart muscle over time.

Trial ID:
2025-524751-32-00
Protocol code:
Epic49
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study of the efficacy and safety of inclisiran and a drug combination in patients with acute coronary syndrome

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Hungary Poland Spain

  • A Study of Intravenous Ferric Carboxymaltose on Quality of Life in Older Adults with Acute Coronary Syndrome and Iron Deficiency

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain